House Rx Hearing Topics Include Generics, DTC And Antihistamine OTC Switch
A House subcommittee will examine FDA's legal authority to switch an Rx drug over-the-counter without the sponsor's consent during a June 13 hearing.
You may also be interested in...
Aventis is pursuing an atopic dermatitis indication for the antihistamine Allegra, Senior VP-Medical & Regulatory Francois Nader, MD, told the FDA OTC switch advisory committee May 11.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials